Vassiliki Smyrni , Vasileios Giannopapas , Dimitrios K. Kitsos , Konstantina Stavrogianni , Athanasios K. Chasiotis , Georgia Papagiannopoulou , Alexandros S. Triantafyllou , Pinelopi Vlotinou , Georgios Tsivgoulis , Anastasios Bonakis , George P. Paraskevas , Sotirios Giannopoulos
{"title":"Prevalence of dysarthria in the multiple sclerosis population: A systematic review and meta-analysis","authors":"Vassiliki Smyrni , Vasileios Giannopapas , Dimitrios K. Kitsos , Konstantina Stavrogianni , Athanasios K. Chasiotis , Georgia Papagiannopoulou , Alexandros S. Triantafyllou , Pinelopi Vlotinou , Georgios Tsivgoulis , Anastasios Bonakis , George P. Paraskevas , Sotirios Giannopoulos","doi":"10.1016/j.msard.2025.106458","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Dysarthria is a common type of motor speech disorder seen in people with MS (PwMS), with studies reporting a prevalence ranging from 40 % to 51 %. There is inconsistent evidence regarding its specific prevalence and its potential association with disability progression and disease duration.</div></div><div><h3>Methods</h3><div>This systematic review and meta-analysis aims to estimate the prevalence of dysarthria in PwMS and to explore potential associations between dysarthria and demographic and disease-specific factors. Adhering to PRISMA guidelines, a detailed search of the MEDLINE PubMed, Cochrane Library, and Scopus databases was conducted.</div></div><div><h3>Results</h3><div>A total of 14 studies involving 1833 MS patients were included, revealing a pooled prevalence of dysarthria in MS of 44.9 % (95 % CI [31.9,58.2], I2=96.2 %, <em>p</em> < 0.00). The aggregated risk ratio of speech disorders in MS patients versus healthy controls was 8.09 (95 %CI [2.40, 27.26], pz=0.0007, I<sup>2</sup>=53 %, <em>p</em> = 0.05. However, meta-regression sensitivity analysis showed no statistically significant associations between speech disorders and age, or disability level but there was evidence of an anti proportional linear relationship between the prevalence of speech disorders and disease duration (<em>p</em> = 0.1)</div></div><div><h3>Conclusion</h3><div>This systematic review and meta-analysis found a 44.9 % prevalence of dysarthria in the MS population; however, no relationship could be established between dysarthria and demographic and disease-specific characteristics. Considering the impact of dysarthria in the quality of life in PwMS, as well as the diagnostic limitations currently existing in clinical practice, this study highlights the necessity for future studies to, systematically and accurately, record dysarthria symptomatology and aetiology in PwMS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"98 ","pages":"Article 106458"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034825002007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Dysarthria is a common type of motor speech disorder seen in people with MS (PwMS), with studies reporting a prevalence ranging from 40 % to 51 %. There is inconsistent evidence regarding its specific prevalence and its potential association with disability progression and disease duration.
Methods
This systematic review and meta-analysis aims to estimate the prevalence of dysarthria in PwMS and to explore potential associations between dysarthria and demographic and disease-specific factors. Adhering to PRISMA guidelines, a detailed search of the MEDLINE PubMed, Cochrane Library, and Scopus databases was conducted.
Results
A total of 14 studies involving 1833 MS patients were included, revealing a pooled prevalence of dysarthria in MS of 44.9 % (95 % CI [31.9,58.2], I2=96.2 %, p < 0.00). The aggregated risk ratio of speech disorders in MS patients versus healthy controls was 8.09 (95 %CI [2.40, 27.26], pz=0.0007, I2=53 %, p = 0.05. However, meta-regression sensitivity analysis showed no statistically significant associations between speech disorders and age, or disability level but there was evidence of an anti proportional linear relationship between the prevalence of speech disorders and disease duration (p = 0.1)
Conclusion
This systematic review and meta-analysis found a 44.9 % prevalence of dysarthria in the MS population; however, no relationship could be established between dysarthria and demographic and disease-specific characteristics. Considering the impact of dysarthria in the quality of life in PwMS, as well as the diagnostic limitations currently existing in clinical practice, this study highlights the necessity for future studies to, systematically and accurately, record dysarthria symptomatology and aetiology in PwMS.
期刊介绍:
Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource.
A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.